{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:55:30Z","timestamp":1790999730648,"version":"4.1.0"},"reference-count":42,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1248\/bpb.b26-00341","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:12:13Z","timestamp":1790979133000},"page":"1601-1609","source":"Crossref","is-referenced-by-count":0,"title":["Engineered Inflammation-Triggering Macrophages (MacTrigger) Synergize Anti-CD47 Immunotherapy While Sparing Normal Tissues"],"prefix":"10.1248","volume":"49","author":[{"given":"Yusuke","family":"Hamabe","sequence":"first","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Nii","sequence":"first","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toma","family":"Yoshimi","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Tanito","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanatsu","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kishimura","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"International Research Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"International Research Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819\u20130395, Japan"},{"name":"Center for Advanced Medical Innovation, Kyushu University, 3\u20131\u20131 Maidashi, Higashi-ku, Fukuoka 812\u20138582, Japan"},{"name":"National Institute of Technology, Kitakyushu College, Fukuoka 802\u20130985, Japan"},{"name":"Department of Biomedical Engineering, Chung Yuan Christian University, 200 Chung Pei Road, Chung Li 32023, ROC, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Chaintreuil P, Kerreneur E, Bourgoin M, Savy C, Favreau C, Robert G, Jacquel A, Auberger P. The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. <i>Front. Immunol<\/i>., <b>14<\/b>, 1178337 (2023).","DOI":"10.3389\/fimmu.2023.1178337"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi A, Afshari JT, Sahebkar A. Macrophage plasticity, polarization, and function in health and disease. <i>J. Cell. Physiol<\/i>., <b>233<\/b>, 6425\u20136440 (2018).","DOI":"10.1002\/jcp.26429"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. <i>J. Exp. Clin. Cancer Res<\/i>.,  <b>44<\/b>, 145 (2025).","DOI":"10.1186\/s13046-025-03377-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. <i>J. Leukoc. Biol.<\/i>, <b>86<\/b>, 1065\u20131073 (2009).","DOI":"10.1189\/jlb.0609385"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Aalipour A, Chuang HY, Murty S, D\u2019Souza AL, Park SM, Gulati GS, Patel CB, Beinat C, Simonetta F, Martini\u0107 I, Gowrishankar G, Robinson ER, Aalipour E, Zhian Z, Gambhir SS. Engineered immune cells as highly sensitive cancer diagnostics. <i>Nat. Biotechnol.<\/i>, <b>37<\/b>, 531\u2013539 (2019).","DOI":"10.1038\/s41587-019-0064-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, Zhao P, Fang L, Shi Y, Wang P. Emerging phagocytosis checkpoints in cancer immunotherapy. <i>Signal Transduct. Target Ther<\/i>., <b>8<\/b>, 104 (2023).","DOI":"10.1038\/s41392-023-01365-z"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. <i>Biomark. Res<\/i>., <b>11<\/b>, 15 (2023).","DOI":"10.1186\/s40364-023-00456-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. <i>J. Hematol. Oncol<\/i>., <b>14<\/b>, 180 (2021).","DOI":"10.1186\/s13045-021-01197-w"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Son J, Hsieh RCE, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Inhibition of the CD47-SIRP\u03b1 axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data. <i>Front. Immunol<\/i>., <b>13<\/b>, 1027235 (2022).","DOI":"10.3389\/fimmu.2022.1027235"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, Majeti R, Weissman I, Mitra SS, Cheshier SH. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages <i>in vivo. PLOS ONE<\/i>, <b>11<\/b>, e0153550 (2016).","DOI":"10.1371\/journal.pone.0153550"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Wu X, Zhong Z, Li Y, Wang Y, Tian Y, Liu X, Zhang X, Tao W, Wang J, Du Y, Zhang S. Injectable scaffolds for <i>in vivo<\/i> programmed macrophages manufacture and postoperative cancer immunotherapy. <i>Adv. Funct. Mater.<\/i>, <b>33<\/b>, 2300058 (2023).","DOI":"10.1002\/adfm.202300058"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tarique AA, Logan J, Thomas E, Holt PG, Sly PD, Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. <i>Am. J. Respir. Cell Mol. Biol.<\/i>, <b>53<\/b>, 676\u2013688 (2015).","DOI":"10.1165\/rcmb.2015-0012OC"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zhang Y, Wang Y, Mu P, Zhu X, Dong Y. Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy. <i>Front. Immunol.<\/i>, <b>15<\/b>, 1470468 (2024).","DOI":"10.3389\/fimmu.2024.1470468"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Liu S, Wang W, Hu S, Jia B, Tuo B, Sun H, Wang Q, Liu Y, Sun Z. Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. <i>Cell Death Dis.<\/i>, <b>14<\/b>, 679 (2023).","DOI":"10.1038\/s41419-023-06211-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, Mahmoodi Chalbatani G, Hejazi E, Webster TJ, Tavakkol-Afshari J, Jalali SA. Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments. <i>PLOS ONE<\/i>, <b>17<\/b>, e0273547 (2022).","DOI":"10.1371\/journal.pone.0273547"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N, Upadhyay S, Horvath A, Kim A, Quiceno-Torres D, Musunuri K, Villagra A. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. <i>Sci. Adv.<\/i>, <b>10<\/b>, eadp3687 (2024).","DOI":"10.1126\/sciadv.adp3687"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gracia-Hernandez M, Yende AS, Gajendran N, Alahmadi Z, Li X, Munoz Z, Tan K, Noonepalle S, Shibata M, Villagra A. Targeting HDAC6 improves anti-CD47 immunotherapy. <i>J. Exp. Clin. Cancer Res.<\/i>, <b>43<\/b>, 60 (2024).","DOI":"10.1186\/s13046-024-02982-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Fang R, Wang C, Jiang Q, Lv M, Gao P, Yu X, Mu P, Zhang R, Bi S, Feng J-M, Jiang Z. NEMO-IKK\u03b2 are essential for IRF3 and NF-\u03baB activation in the cGAS-STING pathway. <i>J. Immunol.<\/i>, <b>199<\/b>, 3222\u20133233 (2017).","DOI":"10.4049\/jimmunol.1700699"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, Woods JM, Haines GK III, Ivashkiv LB. Sensitization of IFN-\u03b3 Jak-STAT signaling during macrophage activation. <i>Nat. Immunol.<\/i>, <b>3<\/b>, 859\u2013866 (2002).","DOI":"10.1038\/ni828"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(Lps+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. <i>Front. Immunol<\/i>., <b>10<\/b>, 1084 (2019).","DOI":"10.3389\/fimmu.2019.01084"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hubenak JR, Zhang Q, Branch CD, Kronowitz SJ. Mechanisms of injury to normal tissue after radiotherapy: a review. <i>Plast. Reconstr. Surg.<\/i>, <b>133<\/b>, 49e\u201356e (2014).","DOI":"10.1097\/01.prs.0000440818.23647.0b"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) C\u0103tan\u0103 A, P\u0103tr\u0103\u0219canu AA, Martin DL, Militaru MS, Iord\u0103nescu II, \u021a\u00eepcu A, Achima\u0219-Cadariu P, P\u00eerlog LM. The impact of genetic variations on radiotherapy toxicity in breast cancer patients: a meta-analysis of acute and late skin adverse effects.. <i>Cancers<\/i>, <b>17<\/b>, 1880 (2025).","DOI":"10.3390\/cancers17111880"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, Zhang W, Yang J. Histone deacetylase 6 in cancer. <i>J. Hematol.Oncol<\/i>., <b>11<\/b>, 111 (2018).","DOI":"10.1186\/s13045-018-0654-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. <i>Pharmaceuticals<\/i>, <b>3<\/b>, 2751\u20132767 (2010).","DOI":"10.3390\/ph3092751"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tanito K, Nii T, Wakuya K, Hamabe Y, Yoshimi T, Hosokawa T, Kishimura A, Mori T, Katayama Y. Inflammation-triggering engineered macrophages (MacTriggers) enhance reactivity of immune checkpoint inhibitor only in tumor tissues. <i>Cancers<\/i>, <b>16<\/b>, 3787 (2024).","DOI":"10.3390\/cancers16223787"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tanito K, Nii T, Yokoyama Y, Oishi H, Shibata M, Hijii S, Kaneko R, Tateishi C, Ito S, Kishimura A, Mori T, Katayama Y. Engineered macrophages acting as a trigger to induce inflammation only in tumor tissues. <i>J. Control. Release<\/i>, <b>361<\/b>, 885\u2013895 (2023).","DOI":"10.1016\/j.jconrel.2023.04.010"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nii T, Yoshimi T, Tanito K, Hijii S, Takata H, Kishimura A, Mori T, Ishida T, Katayama Y. Inflammation-triggering engineered macrophages (MacTriggers) are promising cell-based therapeutic avenues for chemoresistant solid tumors. <i>Anticancer Res.<\/i>, <b>45<\/b>, 1395\u20131405 (2025).","DOI":"10.21873\/anticanres.17525"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Tanito K, Nii T, Kishimura A, Mori T, Katayama Y. Screening of human M2 macrophage-specific markers for preparation of humanized inflammation-triggering engineered macrophage (MacTrigger). <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 966\u2013971 (2025).","DOI":"10.1248\/bpb.b25-00112"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, Li S, Jia L. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. <i>Sci. Rep.<\/i>, <b>9<\/b>, 4532 (2019).","DOI":"10.1038\/s41598-019-40241-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Bess SN, Igoe MJ, Muldoon TJ. Live-cell imaging quantifies changes in function and metabolic NADH autofluorescence during macrophage-mediated phagocytosis of tumor cells. <i>Immunol. Invest.<\/i>, <b>53<\/b>, 210\u2013223 (2024).","DOI":"10.1080\/08820139.2023.2284369"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Sockolosky JT, Dougan M, Ingram JR, Ho CCM, Kauke MJ, Almo SC, Ploegh HL, Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>113<\/b>, E2646\u2013E2654 (2016).","DOI":"10.1073\/pnas.1604268113"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Wang T, Wang SQ, Du YX, Sun DD, Liu C, Liu S, Sun YY, Wang HL, Zhang CS, Liu HL, Jin L, Chen XP. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. <i>J. Transl. Med.<\/i>, <b>22<\/b>, 220 (2024).","DOI":"10.1186\/s12967-023-04710-6"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Xu Z, Gao J, Yao J, Yang T, Wang D, Dai C, Ding Y. Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody. <i>FEBS Open Bio<\/i>, <b>11<\/b>, 813\u2013825 (2021).","DOI":"10.1002\/2211-5463.13084"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. <i>PLOS ONE<\/i>, <b>10<\/b>, e0137345 (2015).","DOI":"10.1371\/journal.pone.0137345"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Graf J, Bomb K, Trautmann-Rodriguez M, Jarai BM, Gill N, Kloxin AM, Fromen CA. Macrophage variance: investigating how macrophage origin influences responses to soluble and physical cues with immortalized <i>vs<\/i>. primary cells in 2D and 3D culture. <i>Front. Biomater. Sci.<\/i>, <b>3<\/b>, 1399448 (2024).","DOI":"10.3389\/fbiom.2024.1458672"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Smith TD, Tse MJ, Read EL, Liu WF. Regulation of macrophage polarization and plasticity by complex activation signals. <i>Integr. Biol. (Camb.)<\/i>, <b>8<\/b>, 946\u2013955 (2016).","DOI":"10.1039\/c6ib00105j"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Oates TCL, Moura PL, Cross S, Roberts K, Baum HE, Haydn-Smith KL, Wilson MC, Heesom KJ, Severn CE, Toye AM. Defining the proteomic landscape of cultured macrophages and their polarization continuum. <i>Immunol. Cell Biol.<\/i>, <b>101<\/b>, 947\u2013963 (2023).","DOI":"10.1111\/imcb.12687"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Liu SX, Gustafson HH, Jackson DL, Pun SH, Trapnell C. Trajectory analysis quantifies transcriptional plasticity during macrophage polarization. <i>Sci. Rep.<\/i>, <b>10<\/b>, 12273 (2020).","DOI":"10.1038\/s41598-020-68766-w"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Yang J, Yao Y, Tong L, Zhu Z, Wang L, Yang J. CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy. <i>Eur. J. Inflamm.<\/i>, <b>19<\/b>, 20587392211000899 (2021).","DOI":"10.1177\/20587392211000899"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kiss B, Van Den Berg NS, Ertsey R, McKenna K, Mach KE, Zhang CA, Volkmer JP, Weissman IL, Rosenthal EL, Liao JC. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer. <i>Clin. Cancer Res.<\/i>, <b>25<\/b>, 3561\u20133571 (2019).","DOI":"10.1158\/1078-0432.CCR-18-3267"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Li Y, Liu J, Chen W, Wang W, Yang F, Liu X, Sheng Y, Du K, He M, Lyu X, Li H, Zhao L, Wei Z, Wang F, Zheng S, Sui J. A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety. <i>J. Hematol. Oncol.<\/i>, <b>16<\/b>, 2 (2023).","DOI":"10.1186\/s13045-023-01399-4"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-kB pathway. <i>FEBS J.<\/i>, <b>278<\/b>, 862\u2013876 (2011).","DOI":"10.1111\/j.1742-4658.2011.08015.x"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00341\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:25:54Z","timestamp":1790997954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00341\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00341","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"article-number":"b26-00341"}}